PDSB PDS Biotechnology Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472091 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.4%
ROA-121.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.62x
Interest coverage-3.52x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-49.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.05M | $3.27M | $3.46M | $4.41M | $4.58M | $4.21M | $5.83M | $4.53M |
| SG&A expense | $3.84M | $3.23M | $3.06M | $2.27M | $3.56M | $3.41M | $3.27M | $2.83M |
| Operating income | -$5.90M | -$6.50M | -$6.52M | -$6.67M | -$8.14M | -$7.62M | -$9.11M | -$7.36M |
| Interest expense | $1.77M | $3.38M | $1.01M | $1.11M | $1.15M | $2.14M | $930,878 | $1.10M |
| Pretax income | -$7.62M | -$9.75M | -$7.35M | -$7.56M | -$9.01M | -$9.43M | -$9.66M | -$7.95M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$1.17M | $0 |
| Net income | -$7.62M | -$9.75M | -$7.35M | -$7.56M | -$9.01M | -$9.43M | -$8.49M | -$7.95M |
| EBITDA | -$5.89M | -$6.49M | -$6.52M | -$6.67M | -$8.13M | -$7.62M | -$9.10M | -$7.36M |
| EPS (basic) | -0.11 | -0.18 | -0.13 | — | -0.19 | -0.21 | -0.21 | — |
| EPS (diluted) | -0.11 | -0.18 | -0.13 | — | -0.19 | -0.21 | -0.21 | — |
| Weighted avg. shares (diluted) | 71.94M | 55.66M | 55.50M | — | 46.87M | 45.90M | 40.52M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.25M | $5.60M | $21.66M | $26.71M | $26.20M | $31.87M | $39.98M | $41.69M |
| Current assets | $18.37M | $7.05M | $22.89M | $28.25M | $27.89M | $33.65M | $42.47M | $45.05M |
| PP&E, net | $168,225 | $176,612 | $114,725 | $120,184 | $125,643 | $131,102 | $136,561 | $142,020 |
| Total assets | $18.57M | $8.81M | $24.66M | $30.49M | $34.71M | $40.48M | $47.03M | $45.36M |
| Current liabilities | $5.08M | $12.38M | $10.15M | $9.48M | $13.33M | $11.53M | $18.27M | $17.09M |
| Total liabilities | $5.08M | $12.39M | $20.77M | $21.24M | $25.25M | $24.52M | $24.67M | $26.35M |
| Shareholders' equity | $13.50M | -$3.58M | $3.89M | $9.25M | $9.45M | $15.96M | $22.36M | $19.00M |
| Shares outstanding | 104.21M | 55.92M | 55.82M | 54.88M | 47.71M | 46.63M | 45.45M | 37.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.22M | -$2.79M | -$4.37M | -$3.70M | -$5.92M | -$9.10M | -$9.03M | -$8.23M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $0 |
| Free cash flow | — | — | — | -$3.70M | -$5.92M | — | — | -$8.23M |
| Investing cash flow | — | — | — | $0 | $0 | — | — | $0 |
| Financing cash flow | $17.87M | -$13.27M | -$679,827 | $4.22M | $241,205 | $995,944 | $7.32M | $172,778 |
| Depreciation & amortization | $8,387 | $8,387 | $5,459 | $5,459 | $5,459 | $5,459 | $5,459 | $5,458 |
| Stock-based compensation | $840,221 | $1.13M | $1.16M | $1.16M | $1.25M | $448,029 | $1.25M | $1.64M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.